Needham Reiterates Buy on RxSight, Maintains $66 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst David Saxon has reiterated a Buy rating on RxSight (NASDAQ:RXST) and maintained a price target of $66.
September 13, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst David Saxon has reiterated a Buy rating on RxSight and maintained a price target of $66, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $66 price target by a reputable analyst suggests a positive outlook for RxSight. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100